Regen-COV-2 Antibody Cocktail Mediated Clearance of SARS-COV-2 in an Immunocompromised Patient.

Autor:	Basheer M; Department of Internal Medicine, Galilee Medical Center, Nahariya, Israel, Biotechnology and Radiology Laboratory, Hadassah Medical Organization and Faculty of Medicine., Saad E; Department of Internal Medicine, Galilee Medical Center, Nahariya, Israel, Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel., Milhem F; Department of Internal Medicine, Galilee Medical Center, Nahariya, Israel., Budman D; Department of Internal Medicine, Galilee Medical Center, Nahariya, Israel., Assy N; Department of Internal Medicine, Galilee Medical Center, Nahariya, Israel, Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
Jazyk:	angličtina
Zdroj:	The Israel Medical Association journal : IMAJ [Isr Med Assoc J] 2022 Nov; Vol. 24 (11), pp. 695-696.
Abstrakt:	Background: Coronavirus disease 2019 (COVID-19) affects different people in different ways. Most infected people develop mild to moderate illness and recover without hospitalization. This case report presents a patient who had difficulty eradicating the corona virus due to being treated with rituximab, which depletes B lymphocytes and therefore disables the production of neutralizing antibodies. The regen-COV-2 antibody cocktail consists of two monoclonal antibodies, casirivimab and imdevimab. This cocktail successfully helped the patient's immune system eradicate the virus without auto specific severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody production. In vitro studies confirm that eradication of the intact the virus. This case report emphases the importance of providing external antiviral antibodies regularly, like the regen-COV-2 antibody cocktail, as post- and even pre- SARS-CoV-2 infection prophylaxis in patients treated with rituximab.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu